publication date: Jul. 20, 2018
Conversation with The Cancer Letter Maha Hussain: OS isn’t a practical endpoint in the context where patients are likely to live 10 years or more
Genevieve Teuton Professor of Medicine and deputy director,
Northwestern University Robert H. Lurie Comprehensive Cancer Center
As a veteran of the FDA Oncologic Drugs Advisory Committee, Maha Hussain took part in the group’s past discussions on treatment options for men with non-metastatic castration-resistant prostate cancer.
“I recall, at the time of one of the ODAC discussions regarding endpoints, somebody asked, ‘What would be the minimum time that would be reasonable to consider as a clinical benefit?’ And, if I recall, my response was, ‘A minimum of a year,’” said Hussain, the Genevieve Teuton Professor of Medicine and deputy director of Northwestern University Robert H. Lurie Comprehensive Cancer Center.
“To say that we delayed metastasis by three months, to me, is not clinically very meaningful, because we have to be mindful of the risks. I think this is an area where we have a gap and an opportunity,” said Hussain. “Ultimately, we have to make sure that the survival … Continue reading Maha Hussain: OS isn’t a practical endpoint in the context where patients are likely to live 10 years or more
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.